Iconic Therapeutics is a biopharmaceutical company built on scientific insight and expertise in Tissue Factor (TF) biology. We are pioneering a new class of TF-targeting molecules that target diseases in which this protein is overexpressed.

Tissue Factor plays a key role in inflammation and pathologic angiogenesis (the formation of abnormal new blood vessels). Prior attempts to regulate this central biological function have been hampered by inability to separate target engagement/inhibition from interference with normal blood coagulation. We have developed a family of monoclonal antibodies to selectively modulate these separate pathways and modify the progression of disease without interfering with normal blood clotting.

We have created a pipeline of therapeutic molecules for acute and chronic inflammation, ophthalmology and cancer.

We have a broad intellectual property portfolio that covers a set of anti-TF monoclonal antibodies that we have discovered in-house. Iconic also has an exclusive license from Yale University to an earlier anti-TF fusion protein.